X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 51 filers reported holding X4 PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $134,000 | -26.0% | 20,638 | -2.1% | 0.00% | 0.0% |
Q1 2021 | $181,000 | +64.5% | 21,078 | +22.7% | 0.00% | 0.0% |
Q4 2020 | $110,000 | +35.8% | 17,172 | +42.7% | 0.00% | 0.0% |
Q3 2020 | $81,000 | -59.3% | 12,034 | -43.5% | 0.00% | -66.7% |
Q2 2020 | $199,000 | +36.3% | 21,314 | +55.9% | 0.00% | +200.0% |
Q4 2019 | $146,000 | – | 13,674 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
RA Capital Management | 559,494 | $3,788,000 | 0.07% |
Bleichroeder LP | 35,730 | $242,000 | 0.04% |